Omeros Corporation

Rigshospitalet

University of Copenhagen

Syddansk Universitet

Kobenhavns Universitet

Københavns Universitet

Peter Garred

Tina Hummelshoj Glue

Mikkel-Ole Skjodt

Tina Hummelshøj Glue

Mikkel-Ole Skjødt

Christian Honore

Christian Honoré

The present invention relates to novel chimeric molecules of ficolin-associated polypeptides, such as fusion polypeptides for the use in the treatment of conditions associated with inflammation, apoptosis, autoimmunity, coagulation, thrombotic or coagulopathic related diseases. The present invention further relates to nucleic acid molecules encoding such fusion polypeptides, vectors and host cells used in the production of the fusion polypeptides.

Chimeric inhibitor molecules of complement activation

The present invention relates to novel ficolin-associated polypeptides, and polypeptides derived from these ficolin-associated polypeptides for the use in the treatment of conditions associated with inflammation, apoptosis, autoimmunity, coagulation, thrombotic or coagulopathic related diseases, as well as the use as biomarkers. The present invention further relates to antibodies recognising such novel ficolin-associated polypeptides, and polypeptides derived thereof, nucleic acid molecules encoding such polypeptides, vectors and host cells used in the production of the polypeptides.

MASP isoforms as inhibitors of complement activation

The present invention relates to methods for detecting Ficolin-3 dependent activation of the lectin pathway of complement, methods for identifying abnormalities in Ficolin-3, and methods for screening for deficiencies/and or identifying abnormalities in any downstream components of the Ficolin-3 dependent activation of the lectin pathway of 5 complement using an acetylated Ficolin-3 ligand, said methods generally comprising the steps of: (a) providing a sample of blood, serum, plasma, another body fluid or an extract thereof; (b) (optionally) preventing in the sample activation of the classical pathway and/or the alternative pathway and/or any non-Ficolin-3 mediated activation of the lectin pathway; (c) acetylating a molecule; (d) contacting said acetylated molecule 10 with said sample, in conditions that permit specific binding of Ficolin-3 to said acetylated molecule, and, (e) detecting and quantifying specific binding of the Ficolin-3 to said acetylated molecule, (f) determining in the sample complement activation and/or deposition by the detection of a C2, C3, C4 and/or a C5 cleavage product and/or by detecting any of the terminal complement complex components C6, C7, C8 or C9 or 15 the C5b-9 terminal complement complex as such. The present invention also provides assays and kits comprising the methods of the invention.

Ficolin-3 assay

Growing community of inventors

Charlottenlund, Denmark

Peter Garred